European Commission Authorizes Ranluspec Strengthening Sandoz Ophthalmology Portfolio and Biosimilar Strategy

Lupin Secures European Commission Approval for Biosimilar Ranibizumab Ranluspec

India-based pharma company Lupin has received approval from the European Commission (EC) for its biosimilar ranibizumab, marketed as Ranluspec, in both vial and pre-filled syringe presentations. The approval follows a recent positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). Ranluspec is indicated for the treatment of multiple ophthalmic conditions, including wet age-related macular degen…

European Commission Authorizes Ranluspec Strengthening Sandoz Ophthalmology Portfolio and Biosimilar Strategy

Open the article to view the coverage from EuropaWire.eu

Lupin receives European Commission approval for biosimilar ranibizumab RanluspecTM

Global pharma major Lupin has announced that it has received approval from the European Commission for its biosimilar ranibizumab, RanluspecTM, for vials and pre-filled syringes. The approval follows a positive opinion from the Committee for Medicinal Products for Human Use. Ranibizumab is a recombinant humanised IgG1 monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A. Its indications include the treatment …